MRVI Maravai Lifesciences (MRVI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001823239
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
What the filings say about MRVI
Insiders, 180 days
-$254.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
Maravai Lifesciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MARAVAI LIFESCIENCES HOLDINGS, INC. insiders sold a net $254.0K of stock across 11 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 9, 2026.
- The trade is 7.4% of the 335,767 shares held after it.
- No other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel ORESHACK KURT sold about $127.5K of MRVI on Jun 10, 2026, the largest insider sale at the company since 2024; 103 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 31, 2025.
- The trade is 6.9% of the 360,767 shares held after it.
- No other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel ORESHACK KURT sold about $126.5K of MRVI on Jun 9, 2026, the largest insider sale at the company since 2024; 103 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 5, 2025.
- The trade is 31.3% of the 155,123 shares held after it.
- 1 other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LUCIER GREGORY T bought about $178.1K of MRVI on Dec 8, 2025; 1 other insider bought within 30 days and 103 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 48.3% of the 106,595 shares held after it.
- 1 other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LUCIER GREGORY T bought about $190.4K of MRVI on Dec 5, 2025; 1 other insider bought within 30 days and 103 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 12, 2025.
- -4.2% median (-4.2% mean) 90-day return after 2 previous buys.
- The trade is 46.3% of the 466,771 shares held after it.
- 1 other insider bought within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Brust Bernd bought about $702.7K of MRVI on Nov 13, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 103 funds added in the latest 13F quarter.11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$254.0K over 180 days
more than 50% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
-28.3% year over year
below 72% of Pharma & Biotech
Margin
-70.4% net margin
below 53% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-27) · 4.5 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MRVI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+117.8%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRVI: institutional holders (13F)
13F holdings, latest reported quarter
20,150,005 sh
$125.7M
9,970,780 sh
$62.2M
8,702,921 sh
$54.3M
7,342,574 sh
$45.8M
7,060,195 sh
$44.1M
Congress trades in MRVI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MRVI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MRVI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Meridian Contrarian Fund
$8.0M position · as of 2026-06-30
1.2%
Lazard US Small Cap Equity Select Portfolio
$337.1K position · as of 2026-06-30
0.9%
Research Affiliates Deletions ETF
$313.0K position · as of 2026-06-30
0.8%
Royce Micro-Cap Fund
$3.2M position · as of 2026-06-30
0.7%
First Eagle Small Cap Opportunity Fund
$21.3M position · as of 2026-07-31
0.7%
Royce Capital Fund - Micro-Cap Portfolio
$1.0M position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Hull
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.4M
$5.8M
$2.4M
-82%
-1%
2021
$1.8M
$2.3M
$1.2M
+40%
+8%
2020
$2.1M
$2.1M
$1.9M
-6%
+9%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $254.0K sold by insiders over 180 days, 103 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MRVI financials
Revenue growth
-28.3%
XBRL, annual
Net margin
-70.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$208.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MRVI
| FY Dec 2025 | $185.7M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $288.9M |
| FY Dec 2022 | $883.0M |
| FY Dec 2021 | $799.2M |
| Jun 2026 | $51.4M |
| Mar 2026 | $65.8M |
| Dec 2025 | $49.9M |
| Sep 2025 | $41.6M |
| Jun 2025 | $47.4M |
| Mar 2025 | $46.9M |
| Dec 2024 | $56.4M |
| Sep 2024 | $69.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-37.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MRVI
| FY Dec 2025 | -70.4% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -47.9% |
| FY Dec 2022 | +55.6% |
| FY Dec 2021 | +58.7% |
| Jun 2026 | -24.1% |
| Mar 2026 | -5.7% |
| Dec 2025 | -71.6% |
| Sep 2025 | -61.4% |
| Jun 2025 | -83.5% |
| Mar 2025 | -63.9% |
| Dec 2024 | -45.8% |
| Sep 2024 | -140.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$35.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MRVI
| FY Dec 2025 | -$70.7M |
| FY Dec 2024 | -$22.2M |
| FY Dec 2023 | $60.7M |
| FY Dec 2022 | $518.9M |
| FY Dec 2021 | $353.7M |
| Jun 2026 | $3.6M |
| Mar 2026 | $4.2M |
| Dec 2025 | -$24.9M |
| Sep 2025 | -$18.8M |
| Jun 2025 | -$13.1M |
| Mar 2025 | -$13.9M |
| Dec 2024 | -$20.5M |
| Sep 2024 | $4.5M |
At each fiscal year end
Single quarter
Debt to equity
0.72x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity MRVI
| FY Dec 2025 | 1.37x |
| FY Dec 2024 | 0.91x |
| FY Dec 2023 | 1.26x |
| FY Dec 2022 | 0.97x |
| FY Dec 2021 | 1.68x |
| Jun 2026 | 0.72x |
| Mar 2026 | 1.14x |
| Dec 2025 | 1.37x |
| Sep 2025 | 1.19x |
| Jun 2025 | 1.11x |
| Mar 2025 | 0.98x |
| Dec 2024 | 0.91x |
| Sep 2024 | 1.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.17x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt MRVI
| FY Dec 2025 | -0.20x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | 1.02x |
| FY Dec 2021 | 0.69x |
| Jun 2026 | -0.17x |
| Mar 2026 | -0.16x |
| Dec 2025 | -0.20x |
| Sep 2025 | -0.17x |
| Jun 2025 | -0.07x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-32.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MRVI
| FY Dec 2025 | -48.7% |
| FY Dec 2024 | -39.0% |
| FY Dec 2023 | -28.8% |
| FY Dec 2022 | +114.0% |
| FY Dec 2021 | +232.3% |
| Jun 2026 | -32.9% |
| Mar 2026 | -40.8% |
| Dec 2025 | -48.7% |
| Sep 2025 | -41.0% |
| Jun 2025 | -54.9% |
| Mar 2025 | -45.7% |
| Dec 2024 | -39.0% |
| Sep 2024 | -56.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-10.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MRVI
| FY Dec 2025 | -14.7% |
| FY Dec 2024 | -11.6% |
| FY Dec 2023 | -7.3% |
| FY Dec 2022 | +23.4% |
| FY Dec 2021 | +29.4% |
| Jun 2026 | -10.3% |
| Mar 2026 | -12.5% |
| Dec 2025 | -14.7% |
| Sep 2025 | -11.4% |
| Jun 2025 | -16.4% |
| Mar 2025 | -13.5% |
| Dec 2024 | -11.6% |
| Sep 2024 | -13.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MRVI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +156.9% |
| FY Dec 2021 | +66.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-16.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MRVI
| FY Dec 2025 | -25.7% |
| FY Dec 2024 | -20.0% |
| FY Dec 2023 | -1.8% |
| FY Dec 2022 | +28.7% |
| FY Dec 2021 | +37.4% |
| Jun 2026 | -16.8% |
| Mar 2026 | -21.5% |
| Dec 2025 | -25.7% |
| Sep 2025 | -19.4% |
| Jun 2025 | -28.9% |
| Mar 2025 | -23.3% |
| Dec 2024 | -20.0% |
| Sep 2024 | -12.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MRVI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 8.57x |
| FY Dec 2021 | 27.03x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value MRVI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield MRVI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MRVI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.11x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2024-09 | 2024-06 | |
|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | n/a | n/a |
| Gross profit | $34.0M | $108.3M | n/a | n/a |
| Operating income | -$215.3M | -$235.6M | n/a | n/a |
| Net income | -$130.8M | -$144.8M | n/a | n/a |
| EPS (diluted) | -0.90 | -1.05 | n/a | n/a |
| Operating cash flow | -$57.6M | $7.5M | n/a | n/a |
| Cash | $216.9M | $322.4M | $578.2M | $573.2M |
| Long-term debt | $286.3M | $290.5M | $516.3M | $517.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
MRVI Stock Sonar score 6/7 axes
Find similar shapesCompareMRVI ranks highest on profitability (71st percentile) and institutional and government (70th), and lowest on insider conviction (24th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRVI filings, in plain words
Are Maravai Lifesciences insiders buying or selling MRVI?
In the 180 days to 2026-10-28, Maravai Lifesciences insiders were net sellers, a net $254.0K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Maravai Lifesciences insiders were net sellers of MRVI, a net $254.0K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
